9th Immunotherapy of Cancer conference (ITOC): A meeting report

被引：2

作者：

Dalloul, Iman ^{[1
,2
]}

Strzalkowski, Thaddaeus Jan Clemens ^{[1
,2
]}

Von Bergwelt-Baildon, Michael ^{[3
,4
]}

Nuessler, Volkmar ^{[5
]}

Zielinski, Christoph ^{[6
]}

Kobold, Sebastian ^{[1
,2
,3
,7
,8
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Univ Hosp, German Ctr Lung Res DZL, Ctr Integrated Prot Sci Munich CIPS M, Munich, Germany

[2] Ludwig Maximilians Univ Munchen, Univ Hosp, German Ctr Lung Res DZL, Div Clin Pharmacol,Dept Med 4, Munich, Germany

[3] German Ctr Translat Canc Res DKTK, Partner Site Munich, Munich, Germany

[4] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany

[5] Tumorzentrum Munchen, Munich, Germany

[6] Wiener Privatklin, Cent European Cooperat Oncol Grp CECOG, Vienna, Austria

[7] Helmholtz Zentrum Munchen, Einheit Klin Pharmakol EKLiP, Munich, Germany

[8] Res Ctr Environm Hlth HMGU, Neuherberg, Germany

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2022年 / 18卷 / 07期

基金：

欧洲研究理事会; 欧盟地平线“2020”;

关键词：

ITOC; immunotherapay; tumor microenvironement; tumor vaccination; cellular therapy; combination therapy;

D O I：

10.1080/21645515.2022.2159706

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The Immunotherapy of Cancer conference (ITOC) is an European meeting providing a global platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and the latest findings about immuno-oncology. The 9th ITOC was held in Munich in September 2022. Major highlights of the 2022 edition included the key note address and life time achievement to Laurence Zitvogel on her contributions on the understanding of the role of microbiota in cancer development and therapy resistance. Her research has paved the way for therapeutic exploitation of the microbiome.

引用

页数：5

共 6 条

[1] Immuno-oncology - An Overview
Kobold, Sebastian
Krackhardt, Angela
Schloesser, Hans
Wolf, Dominik
[J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2018, 143 (14) : 1006 - 1013
[2] Immunotherapy in Tumors Activated T Cells as a New Treatment Modality
Kobold, Sebastian
Duewell, Peter
Schnurr, Max
Subklewe, Marion
Rothenfusser, Simon
Endres, Stefan
[J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2015, 112 (48): : 809 - +
[3] Advances in cancer immunotherapy 2019-latest trends
Kruger, Stephan
Ilmer, Matthias
Kobold, Sebastian
Cadilha, Bruno L.
Endres, Stefan
Ormanns, Steffen
Schuebbe, Gesa
Renz, Bernhard W.
D'Haese, Jan G.
Schloesser, Hans
Heinemann, Volker
Subklewe, Marion
Boeck, Stefan
Werner, Jens
von Bergwelt-Baildon, Michael
[J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
[4] Determinants of response and resistance to CAR T cell therapy
Lesch, Stefanie
Benmebarek, Mohamed-Reda
Cadilha, Bruno L.
Stoiber, Stefan
Subklewe, Marion
Endres, Stefan
Kobold, Sebastian
[J]. SEMINARS IN CANCER BIOLOGY, 2020, 65 : 80 - 90
[5] Cancer immunotherapy using checkpoint blockade
Ribas, Antoni
Wolchok, Jedd D.
[J]. SCIENCE, 2018, 359 (6382) : 1350 - +
[6] CAR T cell therapy in solid tumors: a short review
Umut, Oyku
Gottschlich, Adrian
Endres, Stefan
Kobold, Sebastian
[J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (02) : 143 - 149

← 1 →